GS 9005

Drug Profile

GS 9005

Alternative Names: GS 224338; GS 4338; GS GS '4883

Latest Information Update: 01 Nov 2004

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 23 Oct 2004 Discontinued - Phase-I/II for HIV infections treatment in USA (unspecified route)
  • 13 Jul 2004 Phase-I/II clinical trials in HIV infections treatment in USA (unspecified route)
  • 14 Jan 2004 Gilead has filed an IND with the FDA in the US for HIV infections treatment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top